Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates May 13, 2021
Monopar’s uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study Mar 30, 2021
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates Mar 25, 2021
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery Mar 2, 2021
Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations Feb 18, 2021
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) Feb 16, 2021
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer Feb 11, 2021
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada Feb 9, 2021
Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs Dec 22, 2020
